Abstract
To assess the dynamics of humoral immune responses to inactivated SARS-CoV-2 vaccines across populations with and without prior COVID-19 infection, a longitudinal cohort study was conducted. A total of 38 COVID-19-recovered individuals and 165 naïve participants (without prior COVID-19 infection) were enrolled, all of whom completed a two-dose vaccination regimen. Levels of anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies were analyzed at baseline and post-vaccination time points, including 6 weeks post-first dose, and 1 month and 6 months post-second dose. Among naïve participants, the seropositivity rate for anti-S antibodies increased to 96.23% at 1 month after the second dose with anti-S titers peaking at a median of 54.59 U/mL (p < 0.0001). Conversely, COVID-19-recovered participants exhibited significantly elevated anti-S levels after the first dose (median titer: 637.70 U/mL, p < 0.0001), with no notable changes following the second dose. Anti-S levels in both groups declined by 6 months post-second dose. The dynamic pattern of anti-N antibodies was comparable to that of anti-S, albeit with weaker vaccine-induced responses. Notably, levels of both anti-S and anti-N antibodies decreased with advancing age (p < 0.001). Males demonstrated lower anti-N antibody levels compared with females (p = 0.038), while the presence of underlying diseases was associated with higher anti-S antibody levels (p = 0.030). In conclusion, two doses effectively augmented antibody levels in naïve individuals, whereas a single dose may suffice to confer immune protection in COVID-19-recovered individuals. Antibody levels wane over time, necessitating further investigations into the durability of vaccine-mediated immune protection, evidence-based recommendations for preventive vaccination, and the formulation of immunization strategies tailored to distinct populations.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
